Entering text into the input field will update the search result below

J&J's Tremfya beats Novartis' Cosentyx in late-stage psoriasis study; shares up 1% premarket

Dec. 12, 2018 7:31 AM ETJohnson & Johnson (JNJ) StockBy: Douglas W. House, SA News Editor
  • Results from a Phase 3 clinical trial, ECLIPSE, evaluating Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical's TREMFYA (guselkumab) compared Novartis' (NVS) COSENTYX (secukinumab) in adult patients with moderate-to-severe plaque psoriasis showed TREMFYA's superiority. The data will be presented at the Inflammatory Skin Disease Summit in Vienna.
  • Specifically, 84.5% of patients receiving TREMFYA achieved at least 90% improvement in psoriasis skin surface area (PASI 90) at week 48 versus 70.0% for COSENTYX (p<0.001).
  • TREMFYA demonstrated non-inferiority to COSENTYX on the metric of PASI 75 (at least 75% clearance of psoriasis skin area). 84.6% of patients receiving the former achieved the endpoint compared to 80.2% for the latter at week 12 and week 48. Superiority was not demonstrated (p=0.062).
  • JNJ is up 1% premarket on light volume.
  • Related ticker: (MOR)

Recommended For You

More Trending News

About JNJ Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
JNJ--
Johnson & Johnson